Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
Noosa News14 hours agoShocking moment Bradley Donald Towle arrested after Bruce Hwy rampage and shooting on Sunshine coast
-
General15 hours agoNSW Police to provide update on Sydney woman’s kidnap from Bankstown home and killing
-
Noosa News21 hours agoMollie O’Callaghan admits to doubts, wins gold at Australian Open Swimming Championships
-
Noosa News14 hours agoQueensland woman charged with murdering partner with MND allegedly fed him ‘cocktail’ of medications